Convalescent plasma therapy of a new coronavirus infection: an experience of Moscow city hospitals

Bulanov, A. Yu.; Kostin, Alexander I.; Петриков, С. С.; Lysenko, M.A.; Попугаев, К. А.; Fomina, D.S.; Ладыгина, Е. А.; Simarova, I.B.; Filatova, A.P.; Mutovina, Zinaida Yu.; Kovalevskaya, E. A.; Unmut, S.S.; Maltseva, N.P.; Vasin, E. A.

doi:10.17116/anaesthesiology202006233

Cited by 4 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some studies, no statistically significant improvements in clinical outcomes were observed [21,22,26,28,29,31,33,37,39,40,42,44,46,49,52,53]. In contrast, other studies showed benefits of CovCP in terms of disease progression [23,25,27], mitigation of hypoxia [30], World Health Organization (WHO) severity score [32], respiratory parameters [24,54], rate and time to clinical improvement [20,34], need for intubation [50], extubation rate [35], recovery time from critical illness [55], rate of MV and vasopressor support [51], rate of transfer to MV [41], and clinical status [38] in the overall study population or specific subgroups of patients with COVID-19.…”

Section: Efficacymentioning

confidence: 99%

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

Beraud

Meyer

Lozano

et al. 2022

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Please cite this article as: { doi: https://doi.org/ This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Efficacymentioning

confidence: 99%

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

Beraud

Meyer

Lozano

et al. 2022

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

Intensive Care of Patients with COVID-19

Петриков

Попугаев²,

Zhuravel³

2022

Her. Russ. Acad. Sci.

View full text Add to dashboard Cite

The severe course of COVID-19 requires treatment in emergency and intensive care units. Acute respiratory failure due to the development of pneumonia and acute respiratory distress syndrome is the most common and life-threatening manifestation of the new coronavirus infection. Treatment of patients with severe and extremely severe COVID-19; the use of modern schemes and protocols for drug therapy, mechanical ventilation, and extracorporeal membrane oxygenation; sorption techniques; the use of thermal helium; hemostasis correction; and rehabilitation problems are discussed.

show abstract

Impact of Tocilizumab and convalescent plasma on lung function in severe COVID-19

Lebedev,

Dolya,

Savkov

et al. 2023

Anaes. i reanim.

View full text Add to dashboard Cite

Convalescent plasma therapy of a new coronavirus infection: an experience of Moscow city hospitals

Cited by 4 publications

References 17 publications

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

Lessons learned from the use of convalescent plasma for the treatment of COVID-19 and specific considerations for immunocompromised patients

Intensive Care of Patients with COVID-19

Impact of Tocilizumab and convalescent plasma on lung function in severe COVID-19

Contact Info

Product

Resources

About